Introduction of splicing-switching oligonucleotides that alter BCL-X splicing from BCL-XL to the pro-apoptotic BCL-XS in melanoma cell culture and tumour xenografts was shown to reduce tumour load102. Here, BCL2L1 is linked to melanoma.